Literature DB >> 15691526

Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains.

E Fuller Torrey1, Beata M Barci, Maree J Webster, John J Bartko, James H Meador-Woodruff, Michael B Knable.   

Abstract

BACKGROUND: Previous studies of postmortem neurochemical markers in severe psychiatric disorders have been carried out on different brain collections, making it difficult to compare results.
METHODS: One hundred RNA, protein, and other neurochemical markers were assessed in a single set of 60 postmortem brains (15 each with schizophrenia, bipolar disorder, major depression without psychosis, and unaffected control subjects) in relation to seven neurochemical systems. Quantitative measures of continuous variables for prefrontal, hippocampus, anterior cingulate, superior temporal cortex, or a combination of these were analyzed from published and unpublished studies by 56 research groups.
RESULTS: Before correcting for multiple comparisons, 23% of markers (23/100) were abnormal in one or more regions, with most indicating decreased expression. The largest percentage were associated with the developmental/synaptic (10/22) and gamma-aminobutyric acid (GABA; 3/7) systems. Bipolar disorder (20) and schizophrenia (19) had the most abnormalities, with a 65% overlap. When all brain areas were considered together and corrected for multiple comparisons, reelin, parvalbumin, and GAD67 were the most abnormal.
CONCLUSIONS: Confirming other studies, the GABA and developmental/synaptic neurochemical systems are promising areas for research on schizophrenia and bipolar disorder. Research should include tissue from both diseases, and additional brain areas should be assessed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15691526     DOI: 10.1016/j.biopsych.2004.10.019

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  147 in total

Review 1.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 2.  The contribution of GABAergic dysfunction to neurodevelopmental disorders.

Authors:  Kartik Ramamoorthi; Yingxi Lin
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

3.  Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region.

Authors:  Alice Y Wang; Kathryn M Lohmann; C Kevin Yang; Eric I Zimmerman; Harry Pantazopoulos; Nicole Herring; Sabina Berretta; Stephan Heckers; Christine Konradi
Journal:  Acta Neuropathol       Date:  2011-10-04       Impact factor: 17.088

Review 4.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

5.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

6.  Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability.

Authors:  Valerie M Tatard-Leitman; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Eddie N Billingslea; Susumu Morita; Rachel White; Robert E Featherstone; Rabindranath Ray; Pavel I Ortinski; Anamika Banerjee; Michael J Gandal; Robert Lin; Anamaria Alexandrescu; Yuling Liang; Raquel E Gur; Karin E Borgmann-Winter; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Biol Psychiatry       Date:  2014-07-18       Impact factor: 13.382

Review 7.  Searching for neuropathology: gliosis in schizophrenia.

Authors:  Tatiana P Schnieder; Andrew J Dwork
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

Review 8.  Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; Harvey M Morris
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

10.  Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder.

Authors:  Harvey M Morris; Takanori Hashimoto; David A Lewis
Journal:  Cereb Cortex       Date:  2008-01-17       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.